IBOV 190,100.03 ▲ 1.55% IPSA 10,931.11 ▲ 0.21% IPC MEX 63,828.60 ▼ 0.60% MERVAL 2,781,181 ▲ 0.81% COLCAP 2,514.68 ▼ 0.61% BVL PERÚ 59,751.67 ▲ 0.19% USD/BRL5.22▲ 0.02% USD/MXN18.16▼ 0.73% USD/CLP989.65▲ 0.35% USD/COP3,262▼ 1.53% USD/PEN3.43▼ 0.69% USD/ARS1,524▼ 0.04% USD/UYU40.46▲ 3.55% USD/PYG5,821▲ 2.69% USD/BOB11.93▲ 2.09% USD/DOP59.79▲ 0.49% USD/CRC456.38▲ 3.02% USD/GTQ7.64▲ 3.14% USD/HNL26.86▲ 3.19% USD/NIO36.62▲ 2.63% USD/VES864.39▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.69▲ 1.67% EUR/BRL5.87▲ 0.09% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 190,100.03 ▲ 1.55% IPSA 10,931.11 ▲ 0.21% IPC MEX 63,828.60 ▼ 0.60% MERVAL 2,781,181 ▲ 0.81% COLCAP 2,514.68 ▼ 0.61% BVL PERÚ 59,751.67 ▲ 0.19% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Friday, October 2, 2026

Earnings Market Reports

Lojas Renner, Alupar, And Fleury Q3 2025 Results

Brazil’s latest results from three bellwethers point to an economy moving on multiple tracks. Fashion retailer Lojas Renner

By RT Staff Reporters · November 7, 2025 · 3 min read
Lojas Renner, Alupar, And Fleury Q3 2025 Results
Lojas Renner, Alupar, And Fleury Q3 2025 Results.

Brazil’s latest results from three bellwethers point to an economy moving on multiple tracks. Fashion retailer Lojas Renner is keeping profits steady even as shoppers slow their spending. Power-grid operator Alupar is turning consistent cash generation into dividends.

Diagnostics leader Fleury continues to grow through a mix of acquisitions and digital efficiency, though higher financing costs are clipping the bottom line.

For readers outside Brazil, the through-line is simple: margins and capital discipline now matter as much as raw growth.

Lojas Renner (Retail Apparel And Home) — Profit Holds As Shoppers Catch Their Breath

Renner sells clothing and home goods to the mass market. It reported net income of R$279.4 million ($52 million) and adjusted EBITDA of R$594 million ($110 million), both ahead of expectations, on revenue of R$3.08 billion ($570 million).

Same-store sales rose 3.1% after an unusually strong prior year, hinting that fashion demand is cooling from 2024 highs.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Brazil votes Sunday: Lula 45%, Flávio 40%, and the 50% line”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

The story behind the story: Renner squeezed more out of each real through tighter markdowns, cost control, and better credit operations via its Realize unit.

That margin work offset softer traffic and a milder winter, allowing earnings to beat even as revenue missed some sell-side forecasts.

Read this as a management choice: protect profitability now and wait for the next fashion cycle, rather than chase volumes at any price.

Lojas Renner, Alupar, And Fleury Q3 2025 Results
Lojas Renner, Alupar, And Fleury Q3 2025 Results.
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Alupar (Electricity Transmission) — Dividends As A Signal Of Reliability

Alupar builds and operates regulated transmission lines—predictable, inflation-linked cash flows with long concessions. The board approved interim dividends of R$98.9 million ($18 million), or R$0.10 per common and preferred share and R$0.30 per Unit.

In a high-rate environment, that decision is more than housekeeping: it’s a statement that cash generation and balance-sheet discipline remain intact, even as new projects ramp.

The quiet truth here is strategic positioning. By returning cash with regularity, Alupar anchors yield-seeking investors while keeping enough flexibility to fund growth. It’s a classic regulated-asset play: lower drama, higher visibility.

Fleury (Diagnostic Medicine) — Scale Up Now, Harvest Later

Fleury operates premium and mainstream diagnostics brands across major Brazilian cities. Gross revenue climbed to nearly R$2.4 billion ($444 million), EBITDA reached R$599.4 million ($111 million) with a stable 27.4% margin, and net income came in at R$184.9 million ($34 million).

Operating cash flow was strong at R$718.5 million ($133 million), and capex rose to R$126 million ($23 million) as the group integrated recent deals and invested in IT/Digital.

Mobile collections—tests taken at patients’ homes—now generate 7.8% of revenue, a sticky, convenience-driven channel. The deeper story: management is trading some near-term earnings for durable capacity and productivity.

With net debt around 1.0× EBITDA, Fleury can keep consolidating regional labs while technology lowers unit costs and improves patient experience.

Why this trio matters

Together, these prints sketch Brazil’s late-cycle dynamics. Consumers are choosier, so retailers win on execution, not just assortment.

Regulated infrastructure remains a haven for income investors. And healthcare platforms with balance-sheet room can buy growth and efficiency even when rates are high.

If the Selic rate eases meaningfully in 2026, Renner’s volumes, Alupar’s valuation multiples, and Fleury’s net income could all benefit—each through its own lever. For now, margins, cash fidelity, and disciplined investment are the edges to watch.

Live Company IntelligenceFleury S.A. — the full investor dossierInside: live share price, market cap, three-year financials, valuation, ESG and peer benchmarks — plus the latest Rio Times coverage.
F
◆ Live Company Intelligence
Fleury
SA: FLRY3FLRY3HealthcareDiagnostics & Research28,000 employees
R$12.91B
Market cap

Valuation & profitability

Market capR$12.91B
Revenue (TTM)R$8.79B
P / E ratio20.5
Profit margin8.0%
Return on equity12.6%

Price & risk

52-wk low
$13.01
52-wk high
$23.93
Beta (volatility)0.21
200-day average$16.82

Revenue trend · 6y

20202025
Latest R$8.29B

Ownership

Institutions27.5%
Shares outstanding544M

Dividend

Yield5.3%
Payout ratio90.7%
Fwd. annual$1.61
What Fleury does. Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medicine,…
Data: RT fundamentals (FLRY3.SA) · figures in BRL · as of 2 Oct 2026More company intelligence →

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.

Read More from The Rio Times

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Brazil votes Sunday: Lula 45%, Flávio 40%, and the 50% line”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.